After recovering from breast cancer, women experience greater physical health decline—but how much does that have to do with how their cancer was treated?
As someone who edits and writes for a pharmacy publication, it may seem strange that I am not a pharmacist. Nor do I have experience taking prescription medicines, other than the occasional antibiotic.
According to Melanoma Canada, an estimated 11,300 people were diagnosed with the potentially deadly skin cancer in 2024—up by 17% from the previous year.
People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.
